The FDA is calling for more conservative dosing of erythropoiesis-stimulating agents (ESAs) when used to treat anemia in CKD patients due to the increased risks of cardiovascular events such as stroke, thrombosis, and death.
Clinical trials have demonstrated an increased risk of such events when ESAs are dosed to achieve a normal or nearly normal blood hemoglobin level (10 to 12 g/dL) in patients with CKD.
In addition, the drugs have not been shown to improve quality of life, fatigue, or patient well-being, according to the FDA.
Continue Reading
The recommendations, which will be added to the boxed warning and other sections of the package inserts of epoetin alfa and darbepoetin alfa, now advise practitioners to individual ESA dosing for each patient and use the lowest dose of ESA sufficient to decrease the need for transfusion.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.